Market closedNon-fractional
Tango Therapeutics/TNGX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Tango Therapeutics
Tango Therapeutics Inc is a biotechnology company. It is dedicated towards discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. Its program TNG908, is an MTA-cooperative inhibitor of PRMT5 designed to work selectively in cancer cells with an MTAP deletion. Its pipeline further consists of discovery programs such as, TNG462, TNG348, TNG260 and others for multiple cancer types with limited treatment options.
Ticker
TNGX
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
Boston, United States
Employees
140
Website
www.tangotx.com
TNGX Metrics
BasicAdvanced
$1.1B
Market cap
-
P/E ratio
-$1.12
EPS
0.79
Beta
-
Dividend rate
Price and volume
Market cap
$1.1B
Beta
0.79
Financial strength
Current ratio
8.227
Quick ratio
8.03
Long term debt to equity
13.677
Total debt to equity
14.458
Management effectiveness
Return on assets (TTM)
-19.47%
Return on equity (TTM)
-45.41%
Valuation
Price to revenue (TTM)
26.341
Price to book
3.97
Price to tangible book (TTM)
3.97
Price to free cash flow (TTM)
-8.037
Growth
Revenue change (TTM)
49.72%
Earnings per share change (TTM)
-11.13%
3-year revenue growth (CAGR)
58.61%
3-year earnings per share growth (CAGR)
-7.48%
What the Analysts think about TNGX
Analyst Ratings
Majority rating from 8 analysts.
TNGX Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$6.4M
18.52%
Net income
-$38M
23.45%
Profit margin
-592.18%
4.16%
TNGX Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.23
-$0.23
-$0.32
-$0.35
-
Expected
-$0.34
-$0.35
-$0.28
-$0.31
-$0.34
Surprise
-31.55%
-33.33%
15.21%
11.90%
-
TNGX News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Tango Therapeutics stock?
Tango Therapeutics (TNGX) has a market cap of $1.1B as of July 26, 2024.
What is the P/E ratio for Tango Therapeutics stock?
The price to earnings (P/E) ratio for Tango Therapeutics (TNGX) stock is 0 as of July 26, 2024.
Does Tango Therapeutics stock pay dividends?
No, Tango Therapeutics (TNGX) stock does not pay dividends to its shareholders as of July 26, 2024.
When is the next Tango Therapeutics dividend payment date?
Tango Therapeutics (TNGX) stock does not pay dividends to its shareholders.
What is the beta indicator for Tango Therapeutics?
Tango Therapeutics (TNGX) has a beta rating of 0.79. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.
Buy or sell Tango Therapeutics stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.